Rockefeller Capital Management
KPTI icon

Rockefeller Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Rockefeller Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.08K Hold
733
– – ﹤0.01% 4281
2025
Q4 		$5.39K Buy
+733
New +$4.48K ﹤0.01% 4049
2022
Q3 		– Sell
-60
Closed -$4K – 4150
2022
Q2 		$4K Sell
60
-167
-74% -$15.3K ﹤0.01% 3553
2022
Q1 		$25K Sell
227
-46
-17% -$5.73K ﹤0.01% 2622
2021
Q4 		$26K Buy
273
+26
+11% +$2.59K ﹤0.01% 2517
2021
Q3 		$21K Buy
247
+20
+9% +$2.08K ﹤0.01% 2570
2021
Q2 		$35K Hold
227
– – ﹤0.01% 2237
2021
Q1 		$35K Buy
227
+80
+54% +$16.9K ﹤0.01% 2045
2020
Q4 		$34K Buy
147
+129
+717% +$29.9K ﹤0.01% 1809
2020
Q3 		$3K Buy
18
+7
+64% +$1.71K ﹤0.01% 2338
2020
Q2 		$3K Buy
+11
New +$3.25K ﹤0.01% 2236

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Rockefeller Capital Management's KPTI Position: Q1 2026 in Review

Rockefeller Capital Management held its Karyopharm Therapeutics (KPTI) position steady in Q1 2026 at 733 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4281.

Rockefeller Capital Management first reported a position in KPTI in Q2 2020 and has held it in 11 quarters since. The position peaked at $35K in Q2 2021. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Rockefeller Capital Management held 733 shares of Karyopharm Therapeutics worth $4.08K as of Q1 2026.
  • Rockefeller Capital Management left its Karyopharm Therapeutics share count unchanged in Q1 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4281 holding.
  • Rockefeller Capital Management first reported a position in Karyopharm Therapeutics in Q2 2020 and has held it in 11 quarters since.
  • Rockefeller Capital Management's Karyopharm Therapeutics position peaked at $35K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.